Abstract
Treatment with CAR-T cells represents an innovative therapeutic advance in patients with refractory hematological malignancies. Infectious complications must always be considered and empirically treated. Specific complications such as cytokine release syndrome (CRS) and neurotoxicity can be severe and patients often require intensive care unit admission. A close monitoring is necessary in these patients. While CRS treatment is based on the administration of anti-IL-6 receptor (tocilizumab) in mild forms, corticosteroids are recommended in severe CRS and/or neurotoxicity
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
